Joyce Hamba, NP
Women's Health · Bethesda, MDNPI 1497364400
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.0%), food and beverage and education — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 62.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $1,227 and has fallen 83.6% since, to $201 in 2025. Among women's health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $101.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$206
- Incyte Corporation$145
- G1 Therapeutics, Inc.$124
- Exelixis Inc.$99
- Seagen Inc.$99
- plus $437 from 10 others
What the payments were for
- Consulting fees$1,50051%
- Food & beverage$93632%
- Education$50417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $1,830 |
| Lilly USA, LLC | 2 | $206 |
| Incyte Corporation | 3 | $145 |
| G1 Therapeutics, Inc. | 1 | $124 |
| Exelixis Inc. | 1 | $99 |
| Seagen Inc. | 1 | $99 |
| Daiichi Sankyo Inc. | 4 | $87 |
| Johnson & Johnson | 1 | $80 |
| Merck | 3 | $51 |
| Bristol Myers Squibb | 1 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Genmab U.S., Inc. | 1 | $32 |
| Gilead | 1 | $25 |
| AbbVie | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,940 in reported general payments places this provider in the 95th percentile of 95 women's health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 166 | $4,203 |
| Letrozole | 56 | $1,643 |
| Tamoxifen Citrate | 44 | $1,610 |
| Ondansetron Hcl | 17 | $112 |
| Alendronate Sodium | 23 | $105 |
Paid to pharmacies, not to this prescriber.
Other women's health in Bethesda
- Sarah RogersBethesda$722
- Abby WurzelBethesda$622
- Jasmine WhitcombBaltimore$15K
- Ariel PaskinBaltimore$5K
- Crystal SmithGambrills$4K
- Jamie HuppmannFulton$2K
- Aileen LardisAnnapolis$2K
- Brooke EllingerSilver Spring$2K
- Stephanneth AdamsBaltimore$2K
- Joan LefkofSilver Spring$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.